Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study

Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ TreatmentInvestigator’s Global Assessment (IGA) Materially Improved from Baseline 4 (Severe) to 0 (Clear)Pruritus (itch) Reduced from 5 at baseline to 0, reflecting a complete absence of pruritusHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require ...